Horizon Pharma: latest news - GoINPHARMA
Sunday, 24 March 2019 - 18:33

Horizon Pharma

Horizon Pharma reports excellent quarter, shares rise 4%

Horizon Pharma plc’s shares (Nasdaq) today hit 13.4% and closed at +4.7%, reflecting its excellent second quarter announced by the management. The Ireland-based group posted sales of $289.5m (+12%) and an EPS of $0.41. The current year guidance was increased…

New acquisition for Horizon Pharma ($145m)

Horizon Pharma acquired River Vision for $145m in cash, plus potential future payments contingent on achievement of precise milestones. River Vision’s main asset is anti-inflammatory drug teprotumumab, a mAb inhibitor currently in clinical trial for the treatment of Thyroid Eye…

Horizon Pharma acquires Raptor Pharmaceutical for $800m

Ireland-based Horizon Pharma announced today, before Wall Street opening, that it has acquired California-based Raptor Pharmaceutical Corp for $800m, which corresponds to $9.00 per share in cash, representing a 21% premium to Friday’s closing price. The acquisition has been partly…